ATE185697T1 - Androgentherapie am auge beim sjögrensyndrom - Google Patents

Androgentherapie am auge beim sjögrensyndrom

Info

Publication number
ATE185697T1
ATE185697T1 AT93910732T AT93910732T ATE185697T1 AT E185697 T1 ATE185697 T1 AT E185697T1 AT 93910732 T AT93910732 T AT 93910732T AT 93910732 T AT93910732 T AT 93910732T AT E185697 T1 ATE185697 T1 AT E185697T1
Authority
AT
Austria
Prior art keywords
eye
syndrome
sjögren
androgen therapy
androgen
Prior art date
Application number
AT93910732T
Other languages
English (en)
Inventor
David A Sullivan
Original Assignee
Schepens Eye Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Res Inst filed Critical Schepens Eye Res Inst
Application granted granted Critical
Publication of ATE185697T1 publication Critical patent/ATE185697T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
AT93910732T 1992-04-21 1993-04-21 Androgentherapie am auge beim sjögrensyndrom ATE185697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87165792A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
ATE185697T1 true ATE185697T1 (de) 1999-11-15

Family

ID=25357867

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93910732T ATE185697T1 (de) 1992-04-21 1993-04-21 Androgentherapie am auge beim sjögrensyndrom

Country Status (11)

Country Link
US (1) US5620921C1 (de)
EP (1) EP0643581B1 (de)
JP (1) JPH07508716A (de)
AT (1) ATE185697T1 (de)
AU (1) AU674681B2 (de)
CA (1) CA2133966C (de)
DE (1) DE69326836T2 (de)
DK (1) DK0643581T3 (de)
ES (1) ES2139005T3 (de)
GR (1) GR3032326T3 (de)
WO (1) WO1993020823A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) * 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
JPH08507884A (ja) * 1993-03-12 1996-08-20 アラーガン、インコーポレイテッド フェロモン添加剤を含有するアイケア用品およびその使用方法
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6335348B1 (en) 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US7265150B1 (en) 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US7410995B1 (en) 1998-08-14 2008-08-12 Gpi Nil Holdings Inc. N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6506788B1 (en) 1998-08-14 2003-01-14 Gpi Nil Holdings, Inc. N-linked urea or carbamate of heterocyclic thioesters for vision and memory disorders
AU2183800A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of dry eye
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
US6458854B2 (en) 1999-11-09 2002-10-01 Alcon Universal Ltd. Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use
PL356092A1 (en) 1999-11-09 2004-06-14 Alcon Inc. Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
WO2001034550A2 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders
US6552084B2 (en) 1999-11-09 2003-04-22 Alcon Universal Ltd. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
AU775189B2 (en) 1999-11-09 2004-07-22 Alcon Inc. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
PT1228030E (pt) 1999-11-09 2005-08-31 Alcon Inc Derivados benzenoidicos do acido 15-hidroxieicosatetraenoico e metodos para a sua utilizacao no tratamento das perturbacoes do olho seco
DE60007548T2 (de) 1999-11-09 2004-06-17 Alcon, Inc. Omega kettenmodifizierte hydroxyeicosatetraensäure derivate verwendbar in der behandlung der "trockenes auge" krankheit
WO2001034549A1 (en) 1999-11-09 2001-05-17 Alcon Universal Ltd. Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders
US6803385B2 (en) 1999-11-09 2004-10-12 Alcon, Inc. Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders
JP2003514782A (ja) 1999-11-09 2003-04-22 アルコン，インコーポレイテッド ドライアイの処置のためのリポキシンａ４およびそのアナログ
AU1101301A (en) 1999-11-09 2001-06-06 Alcon Universal Limited 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use
ATE265996T1 (de) 1999-11-09 2004-05-15 Alcon Inc Tri-heteroatom-substituierte und zwei kohlenstoff homologe von 15-hete und verfahren zur verwendung
CA2386636A1 (en) 1999-11-09 2001-05-17 Alcon, Inc. 15-hydroxyeicosatetraenoic acid-related compounds and methods of use
AU1226001A (en) 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
WO2001046134A1 (en) 1999-12-22 2001-06-28 Alcon Universal Ltd. 6-KETO PROSTAGLANDIN F1α AND ANALOGS FOR TREATING DRY EYE
BR0112461A (pt) 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
DK1330246T3 (da) 2000-10-23 2005-08-08 Alcon Inc Anvendelse af hydroxyicosatetraensyrederivater ved intraokulær kirurgi
MXPA03010634A (es) 2001-05-21 2004-03-09 Alcon Inc Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
CA2447883A1 (en) 2001-05-21 2002-11-28 Alcon, Inc. Use of nf-kappa-b inhibitors to treat dry eye disorders
EP1392322A1 (de) * 2001-05-21 2004-03-03 Alcon, Inc. Methode zur behandlung des trockenen auges
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US20030109509A1 (en) * 2001-10-11 2003-06-12 Alcon, Inc. Methods for treating dry eye
WO2003030894A1 (en) * 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US20040248794A1 (en) * 2002-12-20 2004-12-09 Yanni John M. Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells
UY28126A1 (es) * 2002-12-24 2004-06-30 Alcon Inc Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
FR2877574A1 (fr) * 2004-11-08 2006-05-12 Marie Claude Benattar Utilisation d'acide hyaluronique, eventuellement en association avec au moins un androgene pour le traitement de troubles sexuels ou urinaires feminins par amplification du point g et compositions.
EP1858523A1 (de) * 2005-03-02 2007-11-28 Nascent Pharmaceutical, Inc. Kombinationstherapie zur topischen applikation bei der behandlung von trockenen augen
CN103169714A (zh) * 2005-07-12 2013-06-26 Dmi生物科学公司 治疗疾病的方法和产品
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
SI2285364T1 (sl) 2008-05-07 2015-03-31 The Regents Of The University Of California Terapevtska regeneracija in obogatitev lubrikacije okularne površine
BRPI1010086A2 (pt) * 2009-06-22 2018-02-06 Dmi Acquisition Corp método e produtos para tratamento de doenças
DK2554173T3 (en) * 2009-06-22 2017-01-16 Ampio Pharmaceuticals Inc PROCEDURE FOR DISEASE CARE
RU2599036C2 (ru) 2011-01-26 2016-10-10 Аллерган, Инк. Андрогенная композиция для лечения офтальмологического заболевания
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
US20140274985A1 (en) * 2013-03-15 2014-09-18 Raman Malhotra Systemic administration of androgen in treating dry eye syndrome
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
KR20170132319A (ko) * 2015-04-03 2017-12-01 산텐 세이야꾸 가부시키가이샤 난드롤론 또는 그 에스테르, 메테놀론 또는 그 에스테르를 유효 성분으로 하는 드라이아이 치료제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4581226A (en) * 1983-04-07 1986-04-08 Dillon Richard S Method of treating sensitive animal tissue with a specially processed seawater solution
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4863912A (en) * 1986-05-19 1989-09-05 New York Medical College Use of tetrahydrocortisol in glaucoma therapy
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4866049A (en) * 1987-08-10 1989-09-12 Spectra Pharmaceutical Services, Inc. Ophthalmic compositionn and method of using same
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US4951683A (en) * 1989-01-19 1990-08-28 Davis Jeffrey P Device for detecting keratoconjunctivitis sicca

Also Published As

Publication number Publication date
US5620921A (en) 1997-04-15
US5620921C1 (en) 2001-01-09
CA2133966A1 (en) 1993-10-28
JPH07508716A (ja) 1995-09-28
EP0643581B1 (de) 1999-10-20
CA2133966C (en) 1997-09-09
AU674681B2 (en) 1997-01-09
DE69326836D1 (de) 1999-11-25
ES2139005T3 (es) 2000-02-01
DE69326836T2 (de) 2000-02-24
EP0643581A4 (de) 1995-01-11
WO1993020823A1 (en) 1993-10-28
DK0643581T3 (da) 2000-04-25
EP0643581A1 (de) 1995-03-22
AU4112193A (en) 1993-11-18
GR3032326T3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ATE185697T1 (de) Androgentherapie am auge beim sjögrensyndrom
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
NO951592D0 (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
EP0142426A3 (de) Ophthalmische Zusammensetzung enthaltend Norfloxacin und verwandte Antibiotika
DE69214938D1 (de) Mittel zur topischen verabreichung von arzneiwirkstoffen
AU7085996A (en) Therapeutic preparation for the transdermal application of active substances through the skin
SE7600588L (sv) Sett att reglera blodglykoskocentrationer i blod, artificiell betacell samt dator for anvendning i en sadan
IE791235L (en) Acyl-derivatives of carnitine.
IE40860L (en) N- heterocyclylalkylbenzamides
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
IT1177863B (it) Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche
ATE109001T1 (de) Mittel zur stimulierung der tränensekretion.
ATE151977T1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
USD268524S (en) Acupressure instrument for applying rolling pressure to the human body
DK0736033T3 (da) Hidtil ukendte terapeutiske carbohydratblandinger, som er nyttige til afhjælpning af præmenstruelt syndrom
DK0579488T3 (da) Præparat til behandling af mastitis og matritis
TW259710B (de)
IT1148189B (it) 1-(p-2-isopropossietossimetil-fenossi)-3-isopropilammino-propan-2-olo e suoi sali per l'abbassamento della pressione endooculare e preparati oftalmici che li contengono
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
ATE180667T1 (de) Verwendung grenzwertig wirksamer arzneiformen mit betablockern
GB1523001A (en) Foot massage appliance
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.
汪承柏 et al. THE JAUNDICE-SUPPRESSING EFFECT OF BLOOD-COOLING, CIRCULATION-INVIGORATING, VISCERA-DREDGING AND CHOLAGOGIC CHINESE HERBS IN THE TREATMENT OF HEPATITIS
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM